Aastrom Biosciences Receives Orphan Drug Designation from the FDA for Proprietary Bone Marrow Cells Ann Arbor, Michigan, March 23, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM), announced today that the Company's proprietary Tissue Repair Cells (TRCs) received an Orphan Drug Designation from the

Aastrom Has Until October 1, 2009 to Regain Compliance

ANN ARBOR, Mich., Oct. 28, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, announced that the Company received notification from the Listings Qualifications Department of The Nasdaq Stock Market LLC ("NASDAQ") that, given the current

Aastrom Has Until September 18, 2009 to Regain Compliance

ANN ARBOR, Mich., Dec 21, 2007 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that on December 20, 2007, the Company received a deficiency letter from The Nasdaq Stock Market indicating that the minimum

ANN ARBOR, Mich., Jun 18, 2008 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that on June 18, 2008 the Company received a notice from The Nasdaq Stock Market (Nasdaq) informing the Company, that pursuant

-- Study Marks Aastrom's Entry into Vascular Regeneration Marketplace --

-- Study Expands Aastrom's Tumor Antigen Primed Vaccine Approach to Ovarian Cancer --

AASTROM BIOSCIENCES' RECEIVES MANUFACTURING LICENSEAT EUROPEAN PILOT FACILITY FOR PRODUCTION OFPROPRIETARY BONE MARROW STEM CELL PRODUCTS

-- IND Approval Key Milestone for Aastrom's Stem Cell Product Program for Tissue Generation --